Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Perrigo Files NDA for Generic Zegerid

By Pharmaceutical Processing | September 24, 2010

 

Perrigo Company has filed with the FDA an
Abbreviated New Drug Application (ANDA) for omeprazole 20mg/sodium bicarbonate
1100mg, the generic equivalent of Zegerid OTCT, and that it provided prior
notice of this filing to Schering-Plough HealthCare Products, Inc. a subsidiary
of Merck & Co., Inc., the owner of the brand regulatory approval and the Curators
of the University
of Missouri, the listed
patent owner.

On September 20, 2010, Schering-Plough filed suit alleging
patent infringement in the United States District Court of New Jersey to prevent
Perrigo from proceeding with the commercialization of this product. This action
formally initiates the process under the Hatch-Waxman Act. In addition,
Santarus, Inc. and the Curators of the University of Missouri,
licensor and owner of the patents, were joined in the lawsuits as
co-plaintiffs. In connection with litigation relating to [email protected] brand
prescription products, the U.S. District Court for the District of Delaware
ruled in April 2010 that the same patents that are the subject of the present
action were invalid due to obviousness. An appeal of that decision was filed in
May 2010, and the appeal is pending.

The Perrigo product is generic equivalent to
Schering-Plough’s Zegerid-OTCT (omeprazole 20 mg/sodium bicarbonate 1100mg) a
proton pump inhibitor and antacid indicated for the treatment of frequent heartburn.
Sales for the OTC brand are estimated to be approximately $60 million
annualized from the most recent month, according to IRI.

Perrigo’s Chairman and CEO Joseph C. Papa stated, “This
filing is an example of our focus on bringing new Rx to OTC switch products to market.
It is a great addition to our diverse offering of gastrointestinal products.”
 

Related Articles Read More >

FDA logo
Ultra Supplement announces recall for undeclared tadalafil
analyzing medical sample
Expert answers to nitrosamine impurity questions
Cardinal Health
Cardinal Health announces $124M settlement of investors’ opioid suit
FDA logo
FDA warns four companies over selling honey tainted with prescription drugs

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards